Patents by Inventor Mingxing Zhou
Mingxing Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200089436Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: November 25, 2019Publication date: March 19, 2020Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 10592168Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: November 25, 2019Date of Patent: March 17, 2020Assignee: INDIVIOR UK LIMITEDInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 10558394Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: November 21, 2017Date of Patent: February 11, 2020Assignee: INDIVIOR UK LIMITEDInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 10517864Abstract: The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.Type: GrantFiled: June 22, 2018Date of Patent: December 31, 2019Assignee: INDIVIOR UK LIMITEDInventors: Mingxing Zhou, Richard L. Norton
-
Patent number: 10198218Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: December 28, 2017Date of Patent: February 5, 2019Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20190022085Abstract: The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.Type: ApplicationFiled: June 22, 2018Publication date: January 24, 2019Inventors: Mingxing Zhou, Richard L. Norton
-
Patent number: 10172849Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: GrantFiled: March 3, 2016Date of Patent: January 8, 2019Assignee: INDIVIOR UK LIMITEDInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 10168040Abstract: The present disclosure provides a dimming device and a driving and dimming device, where the dimming device includes a communication unit, a microcontrol unit, a power supply unit and a connector, and the power supply unit is input with a mains voltage and outputs a voltage required by the communication unit, the communication unit receives a control signal obtained by wired or wireless transmission and outputs the control signal to the microcontrol unit, the microcontrol unit outputs a dimming signal for dimming, and the connector is detachably connected with a connector of another device.Type: GrantFiled: June 1, 2017Date of Patent: January 1, 2019Assignee: OPPLE LIGHTING CO., LTD.Inventors: Xingxing Xu, Shiwei Yu, Lei Zheng, Zhuang Zuo, Jianlin Xu, Mingxing Zhou, Huiqing Duan
-
Patent number: 10022367Abstract: The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.Type: GrantFiled: March 9, 2015Date of Patent: July 17, 2018Assignee: Indivior UK LimitedInventors: Mingxing Zhou, Richard L. Norton
-
Publication number: 20180157440Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: November 21, 2017Publication date: June 7, 2018Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20180121137Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: December 28, 2017Publication date: May 3, 2018Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 9827241Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: June 14, 2017Date of Patent: November 28, 2017Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 9782402Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: October 25, 2016Date of Patent: October 10, 2017Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20170281618Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: June 14, 2017Publication date: October 5, 2017Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20170268760Abstract: The present disclosure provides a dimming device and a driving and dimming device, where the dimming device includes a communication unit, a microcontrol unit, a power supply unit and a connector, and the power supply unit is input with a mains voltage and outputs a voltage required by the communication unit, the communication unit receives a control signal obtained by wired or wireless transmission and outputs the control signal to the microcontrol unit, the microcontrol unit outputs a dimming signal for dimming, and the connector is detachably connected with a connector of another device.Type: ApplicationFiled: June 1, 2017Publication date: September 21, 2017Applicant: OPPLE LIGHTING CO., LTD.Inventors: Xingxing XU, Shiwei YU, Lei ZHENG, Zhuang ZUO, Jianlin XU, Mingxing ZHOU, Huiqing DUAN
-
Publication number: 20170079976Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: October 25, 2016Publication date: March 23, 2017Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20170079974Abstract: The disclosure provides extended release pharmaceutical formulations comprising an opioid,particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.Type: ApplicationFiled: March 9, 2015Publication date: March 23, 2017Inventors: Mingxing Zhou, Richard L. Norton
-
Patent number: 9498432Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: January 13, 2016Date of Patent: November 22, 2016Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20160184296Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: ApplicationFiled: March 3, 2016Publication date: June 30, 2016Applicant: Indivior UK LimitedInventors: Richard L. Norton, Mingxing Zhou
-
Publication number: 20160128934Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: January 13, 2016Publication date: May 12, 2016Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou